Latest

GE HealthCare Jumps 7.8% as Q3 Growth, Margin Expansion and Raised Guidance Impress Investors GE HealthCare (NASDAQ: GEHC) shares rose

GE HealthCare (NASDAQ: GEHC) shares rose about 7.8% after the company reported stronger-than-expected third-quarter 2026 results and raised its full-year outlook. Revenue increased 7.2%...

10-28-26

Biogen Rises 1% as Revenue Growth Returns and 2026 EPS Guidance Improves Biogen (NASDAQ: BIIB) shares rose about 1% after

Biogen (NASDAQ: BIIB) shares rose about 1% after the company reported double-digit third-quarter revenue growth, strong momentum across its Growth Portfolio and a higher...

10-28-26

UMC Falls 3.4% Despite Strong Q3 Growth as Heavy Capacity Spending Weighs on Shares United Microelectronics (NYSE: UMC) shares fell

United Microelectronics (NYSE: UMC) shares fell about 3.4% even after the company reported strong third-quarter 2026 revenue growth, higher utilization and record contribution from...

10-28-26

Garmin Falls 1.1% Despite Record Q3 Revenue, Margin Expansion and Higher Guidance Garmin (NYSE: GRMN) shares fell about 1.1% even

Garmin (NYSE: GRMN) shares fell about 1.1% even after the company reported record third-quarter 2026 results and raised its full-year outlook. Revenue increased 12%...

10-28-26

TE Connectivity Falls 2.2% Despite Record Q4 Sales, Strong Orders and Double-Digit FY27 Growth Outlook TE Connectivity (NYSE: TEL) shares

TE Connectivity (NYSE: TEL) shares fell about 2.2% despite reporting record fiscal fourth-quarter 2026 sales, strong order growth and a constructive outlook for fiscal...

10-28-26

Aon Rises 3.9% as Organic Growth, Margin Expansion and EPS Gains Drive Strong Q3 Aon (NYSE: AON) shares rose about

Aon (NYSE: AON) shares rose about 3.9% after the company reported solid third-quarter 2026 organic growth, higher adjusted earnings and improving profitability across its...

10-28-26

Boston Scientific Falls 7% as Weak Q3 Growth and Soft Q4 Outlook Pressure Shares Boston Scientific (NYSE: BSX) shares fell

Boston Scientific (NYSE: BSX) shares fell about 7% after the company reported only modest third-quarter 2026 sales growth, lower earnings and a weak fourth-quarter...

10-28-26

American Electric Power Falls 0.7% Despite Strong Q3 Earnings and Higher Long-Term Growth Outlook American Electric Power (NASDAQ: AEP) shares

(NASDAQ: AEP) shares fell about 0.7% even after the company reported stronger third-quarter 2026 earnings and significantly expanded its long-term capital...

10-28-26

Vertiv Jumps 14% as AI Infrastructure Demand Drives 61% Sales Growth and Higher Guidance Vertiv (NYSE: VRT) shares jumped about

Vertiv (NYSE: VRT) shares jumped about 14% after the company reported exceptionally strong third-quarter 2026 growth, with AI data center demand driving record orders,...

10-28-26

GSK Falls 3.7% as Weak Vaccine Sales and Lower Reported Profit Offset Specialty Medicines Growth GSK shares fell about 3.7%

GSK shares fell about 3.7% after the company reported solid third-quarter sales growth but weaker vaccine performance and a sharp decline in reported operating...

10-28-26

Phillips 66 Edges 0.1% Higher as Refining Utilization and Cash Returns Support Q3 Results Phillips 66 (NYSE: PSX) shares rose

Phillips 66 (NYSE: PSX) shares rose about 0.1% after the company reported strong third-quarter operating performance, high refinery utilization and substantial capital returns. Third-quarter...

10-28-26

ADP Falls 2% Despite Strong Fiscal Q1 Results and Higher 2027 Guidance Automatic Data Processing (NASDAQ: ADP) shares fell about

Automatic Data Processing (NASDAQ: ADP) shares fell about 2% even after the company reported stronger-than-expected fiscal first-quarter 2027 results and raised its full-year outlook....

10-28-26

LSE:GSKFollow

GSK Falls 3.7% as Weak Vaccine Sales and Lower Reported Profit Offset Specialty Medicines Growth

GSK shares fell about 3.7% after the company reported solid third-quarter sales growth but weaker vaccine performance and a sharp decline in reported operating profit.

Third-quarter sales rose 4% to £8.9 billion, or 5% at constant exchange rates. Specialty Medicines led growth with sales up 15%, including 10% growth in HIV, 21% growth in Respiratory, Immunology & Inflammation and 23% growth in Oncology.

Vaccines were the main weak spot. Segment sales declined 2%, with Shingrix down 5% and Arexvy falling 24%, partly offset by 12% growth in meningitis vaccines. General Medicines sales were broadly flat.

Core operating profit increased 5% at constant currencies, while core EPS rose just 1% to 54.6p. Reported operating profit fell 16% and reported EPS declined 21%, mainly because of £328 million of restructuring charges tied to the Accelerate Growth programme and lower other operating income.

GSK reaffirmed its 2026 outlook for 3%-5% sales growth and 7%-9% growth in both core operating profit and core EPS. The company also maintained its goal of more than £40 billion in sales by 2031.

The 3.7% decline appears to reflect investor concern over continued weakness in key vaccines, modest core EPS growth and restructuring-related pressure on reported earnings, despite strong Specialty Medicines momentum and unchanged full-year guidance.

💬 🔗

WS Investor 10-28-26

GSK plc announced that its investigational drug bepirovirsen has been accepted for priority review by the U.S. Food and Drug Administration for the treatment of chronic hepatitis B.

The therapy has also received Breakthrough Therapy Designation, highlighting its potential to significantly improve outcomes compared to existing treatments. The application is supported by Phase III trial data showing meaningful functional cure rates in patients.

The FDA has set a target decision date of October 26, 2026. If approved, bepirovirsen could address a major unmet need, as current therapies often require lifelong treatment and have low cure rates.

Source: GSK

💬 🔗

The Investor 04-28-26

GSK announced that its investigational liver therapy efimosfermin has received Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the European Medicines Agency for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

The designations are based on Phase II data showing that once-monthly efimosfermin significantly improved liver fibrosis and helped resolve MASH in patients with moderate to advanced disease, compared to placebo. The therapy also demonstrated a favorable safety profile, with mostly mild and temporary side effects.

MASH, affecting up to 5% of the global population, is a major cause of liver transplants, with limited treatment options currently available—particularly for advanced stages. Efimosfermin is now advancing into Phase III trials, targeting both moderate and severe fibrosis cases, including cirrhosis.

💬 🔗

WS Investor 04-27-26

**GSK's Blenrep Approved in China for Relapsed Multiple Myeloma**

GSK has secured approval from China's National Medical Products Administration (NMPA) for Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) to treat adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The approval followed priority review and Breakthrough Therapy Designation.

The decision is backed by data from the Phase III DREAMM-7 trial, in which BVd nearly tripled median progression-free survival compared to a standard daratumumab-based regimen (36.6 months versus 13.4 months) and reduced the risk of death by 42%. Blenrep is now the only anti-BCMA therapy approved for this patient population in China, and notably the only such treatment administered entirely on an outpatient basis as a 30-minute infusion — reducing the burden on both patients and healthcare facilities.

The approval is particularly significant given that multiple myeloma incidence in China has doubled over the past three decades to around 30,000 new cases annually. Blenrep has now received more than 15 regulatory approvals globally, including in the US, EU, UK, and Japan.

💬 🔗

WS Investor 04-20-26

London, April 15, 2026 — GSK announced the completion of its $950 million acquisition of 35Pharma, strengthening its pipeline in respiratory and inflammatory diseases.

The deal includes HS235, a clinical-stage therapy targeting pulmonary hypertension (PH), a serious condition affecting around 82 million people globally. The drug focuses on the activin receptor signalling pathway and is designed to improve safety by reducing risks associated with current treatments, such as bleeding.

GSK said HS235 could also offer broader metabolic benefits, including improved insulin sensitivity and fat-selective weight loss, based on early clinical findings. Proof-of-concept trials are expected to begin soon across multiple forms of PH.

The acquisition supports GSK’s strategy to expand its portfolio in chronic diseases and address significant unmet medical needs in pulmonary and cardiovascular conditions.

💬 🔗

European Investor 04-15-26

GSK plc announced that China’s National Medical Products Administration has approved Exdensur (depemokimab) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), marking the first ultra-long-acting biologic available for this condition in the country.

The approval allows Exdensur to be used as an add-on therapy for patients who do not achieve adequate disease control with corticosteroids or surgery. The decision is based on Phase III ANCHOR trials, which demonstrated statistically significant reductions in nasal polyp size and improvements in nasal obstruction symptoms over a 52-week period.

Exdensur, administered twice yearly, targets type 2 inflammation by inhibiting interleukin-5 (IL-5), offering a long-lasting treatment option for patients with persistent symptoms. The therapy has shown a safety profile comparable to standard care in clinical studies.

The drug has already received approvals in multiple markets, including the United States, Japan, the European Union, and the UK, for respiratory conditions such as severe asthma and CRSwNP.

💬 🔗

The Investor 04-08-26

GSK announced that China has approved Exdensur (depemokimab) for the treatment of severe asthma with an eosinophilic phenotype.

Exdensur is the first ultra-long-acting biologic in China for this condition, requiring only two doses per year, which could significantly improve treatment convenience and adherence.

The approval is based on Phase III SWIFT trials, where the drug reduced asthma exacerbations by up to 58% compared to placebo and showed strong safety and tolerability.

With more than 2 million severe asthma patients in China, the approval expands GSK’s footprint in respiratory medicine and supports its strategy to redefine treatment standards through long-acting biologics.

💬 🔗

The Investor 03-31-26

GSK plc announced that the European Medicines Agency has accepted for review its investigational therapy Bepirovirsen for the treatment of chronic hepatitis B.

The submission is supported by Phase III B-Well trials, which showed statistically significant and clinically meaningful functional cure rates compared with standard of care alone. The therapy also demonstrated an acceptable safety and tolerability profile.

Bepirovirsen is a potential first-in-class treatment designed to target and suppress hepatitis B virus activity while enabling the immune system to regain control of the infection.

Chronic hepatitis B affects millions of people in Europe and remains a leading cause of liver cancer, with current treatments often requiring lifelong therapy. A regulatory decision on the application is expected following the EMA review process.

💬 🔗

The Investor 03-27-26

GSK announced that its investigational antibody-drug conjugate, risvutatug rezetecan, has received Orphan Drug Designation in Japan for the treatment of small-cell lung cancer.

The designation is supported by early clinical data showing durable responses in patients with extensive-stage disease, a condition with limited treatment options and poor prognosis.

The milestone marks the sixth global regulatory designation for the therapy, reinforcing its potential across multiple solid tumor indications and supporting its ongoing clinical development.

💬 🔗

WS Investor 03-23-26

GSK announced that the U.S. Food and Drug Administration has expanded approval of its RSV vaccine, Arexvy, to adults aged 18–49 who are at increased risk of severe respiratory disease.

The vaccine was previously approved for adults aged 60 and older and for adults aged 50–59 with certain risk factors. The expanded indication addresses a significant population, with an estimated 21 million adults under 50 in the U.S. having at least one condition that increases the risk of severe RSV infection.

The FDA decision was supported by Phase III trial data showing immune responses in adults aged 18–49 were comparable to those in older adults. GSK said the approval supports its strategy to broaden RSV prevention across wider adult populations and reduce the burden of the disease on healthcare systems.

💬 🔗

The Investor 03-13-26

Load More

NYSE:GSKFollow

Track all markets on TradingView - Prices are not updated in real time

GSK Falls 3.7% as Weak Vaccine Sales and Lower Reported Profit Offset Specialty Medicines Growth

GSK shares fell about 3.7% after the company reported solid third-quarter sales growth but weaker vaccine performance and a sharp decline in reported operating profit.

Third-quarter sales rose 4% to £8.9 billion, or 5% at constant exchange rates. Specialty Medicines led growth with sales up 15%, including 10% growth in HIV, 21% growth in Respiratory, Immunology & Inflammation and 23% growth in Oncology.

Vaccines were the main weak spot. Segment sales declined 2%, with Shingrix down 5% and Arexvy falling 24%, partly offset by 12% growth in meningitis vaccines. General Medicines sales were broadly flat.

Core operating profit increased 5% at constant currencies, while core EPS rose just 1% to 54.6p. Reported operating profit fell 16% and reported EPS declined 21%, mainly because of £328 million of restructuring charges tied to the Accelerate Growth programme and lower other operating income.

GSK reaffirmed its 2026 outlook for 3%-5% sales growth and 7%-9% growth in both core operating profit and core EPS. The company also maintained its goal of more than £40 billion in sales by 2031.

The 3.7% decline appears to reflect investor concern over continued weakness in key vaccines, modest core EPS growth and restructuring-related pressure on reported earnings, despite strong Specialty Medicines momentum and unchanged full-year guidance.

💬 🔗

WS Investor 10-28-26

GSK Stock Rises 6.4% as Strong Specialty Medicines Growth and R&D Expansion Boost Confidence

GSK (NYSE: GSK) shares rose 6.4% on Tuesday after the pharmaceutical company reported solid second-quarter results, reaffirmed its full-year guidance, and unveiled plans to accelerate research and development while expanding its late-stage pipeline.

Second-quarter sales increased 5% to £8.4 billion, driven by continued strength in Specialty Medicines and Vaccines. Core operating profit rose 7%, while core EPS increased 9% to 50.5 pence, reflecting higher sales and a favorable product mix despite increased investment in research and development and new product launches. Operating cash flow reached £2.9 billion, with free cash flow totaling £2.0 billion.

Specialty Medicines remained the company’s primary growth engine, with sales climbing 14% to £3.8 billion. Respiratory, Immunology & Inflammation revenue increased 19%, Oncology sales grew 17%, and HIV revenue advanced 10%. Vaccines also delivered a strong performance, with sales rising 8%, supported by robust demand for meningitis vaccines and Arexvy, whose sales more than doubled year over year. General Medicines revenue declined 9%, largely reflecting lower sales of Trelegy and other mature products.

While reported operating profit fell 75% and reported EPS declined 69%, the weakness was primarily driven by a £1.3 billion impairment related to camlipixant and other one-time charges rather than deterioration in the underlying business. Investors instead focused on the company’s improving core performance and strong cash generation.

GSK also announced an ambitious acceleration of its research pipeline. The company now expects to launch more than 20 Phase III clinical trials during 2026, double its previous target, while identifying seven priority assets across 18 indications for accelerated development. Management also announced plans to establish a new flagship R&D center at the Cambridge Biomedical Campus in the UK and introduced a restructuring program targeting £1.9 billion in annual cost savings by 2029.

The company reaffirmed its 2026 guidance, forecasting revenue growth of 3% to 5%, core operating profit growth of 7% to 9%, and core EPS growth of 7% to 9%. Management also reiterated confidence in achieving more than £40 billion in annual sales by 2031.

The strong share price reaction suggests investors looked beyond the headline impairment charges and focused on GSK’s accelerating pharmaceutical pipeline, robust growth in Specialty Medicines, improving profitability, and management’s confidence in sustaining long-term earnings growth.

💬 🔗

WS News 07-28-26

GSK plc announced that its investigational drug bepirovirsen has been accepted for priority review by the U.S. Food and Drug Administration for the treatment of chronic hepatitis B.

The therapy has also received Breakthrough Therapy Designation, highlighting its potential to significantly improve outcomes compared to existing treatments. The application is supported by Phase III trial data showing meaningful functional cure rates in patients.

The FDA has set a target decision date of October 26, 2026. If approved, bepirovirsen could address a major unmet need, as current therapies often require lifelong treatment and have low cure rates.

Source: GSK

💬 🔗

The Investor 04-28-26

GSK announced that its investigational liver therapy efimosfermin has received Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the European Medicines Agency for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

The designations are based on Phase II data showing that once-monthly efimosfermin significantly improved liver fibrosis and helped resolve MASH in patients with moderate to advanced disease, compared to placebo. The therapy also demonstrated a favorable safety profile, with mostly mild and temporary side effects.

MASH, affecting up to 5% of the global population, is a major cause of liver transplants, with limited treatment options currently available—particularly for advanced stages. Efimosfermin is now advancing into Phase III trials, targeting both moderate and severe fibrosis cases, including cirrhosis.

💬 🔗

WS Investor 04-27-26

**GSK's Blenrep Approved in China for Relapsed Multiple Myeloma**

GSK has secured approval from China's National Medical Products Administration (NMPA) for Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) to treat adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The approval followed priority review and Breakthrough Therapy Designation.

The decision is backed by data from the Phase III DREAMM-7 trial, in which BVd nearly tripled median progression-free survival compared to a standard daratumumab-based regimen (36.6 months versus 13.4 months) and reduced the risk of death by 42%. Blenrep is now the only anti-BCMA therapy approved for this patient population in China, and notably the only such treatment administered entirely on an outpatient basis as a 30-minute infusion — reducing the burden on both patients and healthcare facilities.

The approval is particularly significant given that multiple myeloma incidence in China has doubled over the past three decades to around 30,000 new cases annually. Blenrep has now received more than 15 regulatory approvals globally, including in the US, EU, UK, and Japan.

💬 🔗

WS Investor 04-20-26

London, April 15, 2026 — GSK announced the completion of its $950 million acquisition of 35Pharma, strengthening its pipeline in respiratory and inflammatory diseases.

The deal includes HS235, a clinical-stage therapy targeting pulmonary hypertension (PH), a serious condition affecting around 82 million people globally. The drug focuses on the activin receptor signalling pathway and is designed to improve safety by reducing risks associated with current treatments, such as bleeding.

GSK said HS235 could also offer broader metabolic benefits, including improved insulin sensitivity and fat-selective weight loss, based on early clinical findings. Proof-of-concept trials are expected to begin soon across multiple forms of PH.

The acquisition supports GSK’s strategy to expand its portfolio in chronic diseases and address significant unmet medical needs in pulmonary and cardiovascular conditions.

💬 🔗

European Investor 04-15-26

GSK plc announced that China’s National Medical Products Administration has approved Exdensur (depemokimab) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), marking the first ultra-long-acting biologic available for this condition in the country.

The approval allows Exdensur to be used as an add-on therapy for patients who do not achieve adequate disease control with corticosteroids or surgery. The decision is based on Phase III ANCHOR trials, which demonstrated statistically significant reductions in nasal polyp size and improvements in nasal obstruction symptoms over a 52-week period.

Exdensur, administered twice yearly, targets type 2 inflammation by inhibiting interleukin-5 (IL-5), offering a long-lasting treatment option for patients with persistent symptoms. The therapy has shown a safety profile comparable to standard care in clinical studies.

The drug has already received approvals in multiple markets, including the United States, Japan, the European Union, and the UK, for respiratory conditions such as severe asthma and CRSwNP.

💬 🔗

The Investor 04-08-26

GSK announced that China has approved Exdensur (depemokimab) for the treatment of severe asthma with an eosinophilic phenotype.

Exdensur is the first ultra-long-acting biologic in China for this condition, requiring only two doses per year, which could significantly improve treatment convenience and adherence.

The approval is based on Phase III SWIFT trials, where the drug reduced asthma exacerbations by up to 58% compared to placebo and showed strong safety and tolerability.

With more than 2 million severe asthma patients in China, the approval expands GSK’s footprint in respiratory medicine and supports its strategy to redefine treatment standards through long-acting biologics.

💬 🔗

The Investor 03-31-26

GSK plc announced that the European Medicines Agency has accepted for review its investigational therapy Bepirovirsen for the treatment of chronic hepatitis B.

The submission is supported by Phase III B-Well trials, which showed statistically significant and clinically meaningful functional cure rates compared with standard of care alone. The therapy also demonstrated an acceptable safety and tolerability profile.

Bepirovirsen is a potential first-in-class treatment designed to target and suppress hepatitis B virus activity while enabling the immune system to regain control of the infection.

Chronic hepatitis B affects millions of people in Europe and remains a leading cause of liver cancer, with current treatments often requiring lifelong therapy. A regulatory decision on the application is expected following the EMA review process.

💬 🔗

The Investor 03-27-26

GSK announced that its investigational antibody-drug conjugate, risvutatug rezetecan, has received Orphan Drug Designation in Japan for the treatment of small-cell lung cancer.

The designation is supported by early clinical data showing durable responses in patients with extensive-stage disease, a condition with limited treatment options and poor prognosis.

The milestone marks the sixth global regulatory designation for the therapy, reinforcing its potential across multiple solid tumor indications and supporting its ongoing clinical development.

💬 🔗

WS Investor 03-23-26

Load More

06-09-26Global Finance News

USFollow

U.S. Stocks Trade Mixed as Wider Trade Deficit Offsets Inventory Growth

U.S. stocks were mixed after fresh economic data showed a wider-than-expected goods trade deficit alongside stronger retail inventory growth. The S&P 500 rose 0.15% and the Dow gained 0.27%, while the Nasdaq was nearly unchanged, down 0.01%.

The U.S. goods trade deficit widened to $134.90 billion in September, larger than the $130.40 billion consensus estimate and the previous $132.07 billion deficit. The deterioration suggests imports continued to outpace exports and could weigh on the trade component of third-quarter GDP calculations.

Retail inventories excluding autos increased 0.4% in September, accelerating from 0.1% previously. Higher inventories can provide some near-term support to GDP, although persistent inventory accumulation can become a negative signal if it reflects weaker-than-expected final demand.

Overall, the releases offered a mixed economic signal: stronger inventory accumulation was offset by a larger trade deficit, helping explain the relatively subdued reaction across major U.S. equity indexes.

💬 🔗

WS Investor 10-28-26

Wall Street Rises as Strong Consumer Confidence Offsets Mixed U.S. Economic Data

U.S. stocks moved higher Tuesday, with the Nasdaq gaining 1.19%, the S&P 500 rising 0.66% and the Dow Jones adding 0.14%, as investors digested a mixed batch of economic data.

Conference Board Consumer Confidence climbed to 91.7 in October, well above the 81.2 forecast and up from 84.2 previously. The stronger-than-expected reading pointed to improved household sentiment and provided the clearest positive signal from the day’s releases.

New home sales also came in better than expected at an annualized 676,000 in September, compared with the 651,000 forecast, although sales edged down from 680,000 previously.

Other indicators were softer. Building permits slipped to 1.398 million, slightly below the 1.400 million forecast and 1.403 million prior reading. Weekly ADP employment growth slowed to 16,800 from 18,500, suggesting some moderation in private-sector hiring.

Durable goods orders rose 1.8% in September, a sharp improvement from the prior 0.1% increase but slightly below the 2.0% consensus estimate.

Overall, the data presented a mixed economic picture, with stronger consumer confidence and housing demand offsetting softer employment and building activity. The stronger move in the Nasdaq suggests risk appetite remained relatively firm despite the uneven macro signals.

💬 🔗

European Investor 10-27-26

Wall Street Falls as Mixed Jobless Claims and Surging Oil Keep Rate and Inflation Concerns in Focus

U.S. stocks traded lower after the latest labor-market data sent a mixed signal while a sharp rise in crude oil added to inflation concerns.

Initial jobless claims fell to 194,000, better than the 200,000 consensus estimate and down from 200,000 previously. The reading suggests layoffs remain relatively contained and the labor market is still holding up.

Continuing jobless claims, however, rose to 1.728 million, above the 1.720 million forecast and up from 1.703 million previously. That points to some difficulty for unemployed workers in finding new jobs even as new layoffs remain low.

Equities were under pressure, with the S&P 500 down about 0.78%, the Dow Jones Industrial Average off 0.15%, and the Nasdaq falling roughly 1.42%. The heavier Nasdaq decline suggests continued pressure on rate-sensitive growth and technology stocks.

At the same time, Brent crude climbed about 2.4% to $111.48 per barrel. Higher oil prices can complicate the inflation outlook by increasing energy and transportation costs, potentially reinforcing concerns that the Federal Reserve may need to keep monetary policy restrictive for longer.

Overall, the combination of resilient initial claims and rising oil prices appears to be weighing on risk appetite, even as the increase in continuing claims points to some underlying softening in the labor market.

💬 🔗

WS News 10-22-26

Wall Street Trades Mixed as Hotter PPI and Strong Retail Sales Reinforce Rate Concerns

U.S. stocks traded mixed after a batch of economic data showed stronger consumer spending, hotter producer inflation and continued labor-market resilience. The S&P 500 fell 0.26% to 7,698.99 and the Nasdaq dropped 0.86% to 26,463.05, while the Dow Jones Industrial Average rose 0.55% to 51,907.65.

September retail sales increased 0.8% month over month, well above the 0.3% consensus estimate, although growth slowed from 1.3% previously. Core retail sales rose 0.9%, also beating the 0.6% forecast but easing from 1.4%.

Inflation data were more concerning. Producer prices jumped 1.3% month over month, more than double the 0.6% expected and sharply above the prior 0.5% increase. Core PPI rose 0.7%, compared with a 0.3% forecast and 0.2% previously.

The labor market remained firm. Initial jobless claims were 199,000, matching expectations and little changed from 198,000, while continuing claims came in at 1.710 million, exactly in line with forecasts and slightly below 1.714 million previously.

Manufacturing data were also much stronger than expected, with the New York Empire State Manufacturing Index jumping to 25.5 in October from 7.6, far above the 12.1 consensus estimate.

The data combination points to an economy that remains resilient but is also experiencing renewed inflation pressure. That backdrop may reinforce expectations for interest rates to remain elevated for longer, which appears to be weighing particularly on the rate-sensitive Nasdaq even as the Dow moves higher.

💬 🔗

The Investor 10-15-26

Wall Street Falls as September Inflation Comes in Hotter Than Expected

U.S. stocks moved lower after September inflation data showed broader price pressures remained firmer than economists expected. The S&P 500 fell 0.76% to 7,745.85, while the Nasdaq dropped 0.99% to 26,934.31. The Dow Jones Industrial Average declined 0.14% to 51,597.18.

Headline CPI increased 0.6% month over month in September, matching expectations but accelerating from 0.4% in August. On a year-over-year basis, inflation rose to 3.7%, above the 3.6% consensus estimate and up from 3.4% previously.

More importantly for the Federal Reserve outlook, core inflation also came in hotter than expected. Core CPI rose 0.3% month over month versus the 0.2% forecast, while the annual core rate accelerated to 2.6% from 2.4%, also exceeding the 2.5% consensus estimate.

The combination of higher headline inflation and an upside surprise in core prices suggests underlying inflation pressures remain persistent. That could reduce expectations for near-term monetary easing or reinforce the case for keeping interest rates elevated for longer.

The Nasdaq’s larger decline is consistent with renewed rate concerns weighing more heavily on growth and technology stocks, while the relatively smaller move in the Dow suggests a more defensive market response.

💬 🔗

Global Finance News 10-14-26

Wall Street Trades Mixed as U.S. Housing Data Beats Expectations

U.S. stocks traded mixed Tuesday as investors digested stronger-than-expected housing data alongside another increase in weekly private-sector employment.

The S&P 500 slipped 0.07% to 7,801.82, while the Nasdaq Composite fell 0.11% to 27,217.00. The Dow Jones Industrial Average was slightly higher, gaining 0.04% to 51,868.87.

U.S. existing home sales increased to an annualized 3.99 million units in September, above expectations of 3.95 million and up from 3.93 million previously. On a monthly basis, sales rose 1.5%, significantly stronger than the expected 0.8% decline and reversing the previous month’s 3.2% drop.

Separately, ADP’s weekly employment measure showed private payrolls increasing by 24,800, up from 23,800 in the previous reading.

The data points to continued resilience in parts of the U.S. economy, particularly housing and employment. However, the relatively muted equity-market reaction suggests investors remain cautious about how stronger economic activity could influence the Federal Reserve’s interest-rate outlook.

💬 🔗

European Investor 10-13-26

U.S. Consumer Sentiment Weakens in October as Inflation Expectations Stay Elevated

The University of Michigan’s preliminary Consumer Sentiment Index fell to 46.3 in October, below the 47.5 consensus estimate and down from 48.1 previously.

Consumer expectations were somewhat more resilient, rising to 47.3 from 46.3 and beating the 45.9 forecast. That suggests households became slightly less pessimistic about the outlook even as overall sentiment deteriorated.

One-year inflation expectations edged up to 4.7% from 4.6%, although the reading came in slightly below the 4.8% consensus estimate.

The report gives a mixed signal for markets. Softer headline sentiment points to continued caution among U.S. consumers, while the improvement in expectations offers some support to the growth outlook. However, inflation expectations remain elevated, which could keep investors sensitive to additional price-pressure data and complicate expectations for faster monetary easing.

💬 🔗

WS News 10-09-26

U.S. Stocks Edge Higher as Brent Crude Holds Near $104

U.S. stocks opened modestly higher on Thursday, with the S&P 500 up 0.27% at 7,786.27, the Dow Jones Industrial Average gaining 0.28% to 51,375.78, and the Nasdaq rising 0.34% to 27,285.85.

Brent crude was trading at $103.89 per barrel, down 0.37% on the day, after moving between roughly $102.50 and $103.90 during the session. Oil remains at elevated levels despite the slight decline.

The combination of firm equity markets and Brent holding above $100 suggests investors are balancing resilient risk appetite against continued inflation concerns from high energy prices. Elevated crude can increase transportation and input costs across the economy, potentially keeping some pressure on headline inflation.

For equities, the near-term question is whether oil prices stabilize around current levels or resume their recent rise. A renewed move higher in crude could revive concerns over inflation and interest rates, while a pullback would provide some relief to broader market sentiment.

💬 🔗

Global Finance News 10-09-26

U.S. Stocks Mixed as Rising Oil Prices Revive Inflation Concerns

U.S. stocks traded mixed on Thursday as investors weighed resilient labor-market data against a sharp rise in oil prices that renewed concerns about inflation.

The S&P 500 fell 0.17% to 7,788.26 and the Nasdaq declined 0.43% to 27,421.53, while the Dow Jones edged up 0.08% to 51,219.42.

Initial jobless claims came in at 197,000, below the 200,000 consensus and down from 199,000 previously, suggesting layoffs remain relatively limited. Continuing claims, however, increased to 1.716 million from 1.699 million, slightly above expectations of 1.710 million, pointing to somewhat softer re-employment conditions.

Oil added another source of pressure. Brent crude surged about 4.6% to roughly $104.83 per barrel during the session. The sharp increase raised concerns that higher energy costs could feed back into headline inflation and transportation costs, potentially slowing the disinflation process.

The combination of firm initial claims and rising oil prices is not particularly supportive for aggressive Federal Reserve easing. Investors appear to be balancing continued economic resilience against the risk that renewed energy inflation could keep interest rates higher for longer, which is especially relevant for rate-sensitive technology and growth stocks.

💬 🔗

European Investor 10-08-26

Wall Street Turns Lower as Inflation Expectations Rise and 10-Year Treasury Yield Jumps

U.S. stocks moved lower Wednesday as investors reacted to higher consumer inflation expectations and a sharp increase in the yield at the latest 10-year Treasury note auction.

The S&P 500 fell 0.24% to 7,800.42, while the Dow Jones Industrial Average declined 0.59% to 51,219.02. The Nasdaq Composite was down 0.39% at 27,492.49.

The New York Fed’s one-year consumer inflation expectations rose to 3.9% in September, above both the 3.6% forecast and the previous reading of 3.6%. The increase suggests households are becoming more concerned about near-term price pressures, potentially complicating the Federal Reserve’s path toward easier monetary policy.

Pressure on markets was reinforced by the U.S. Treasury’s 10-year note auction, which cleared at a yield of 5.300%, sharply above the previous auction’s 4.834%. The higher yield points to materially higher borrowing costs and increases the discount rate applied to future corporate earnings, a particular headwind for growth-oriented equities.

The combination of rising inflation expectations and higher long-term Treasury yields appears to be weighing on risk sentiment, with investors reassessing the possibility that U.S. interest rates may remain elevated for longer than previously anticipated.

💬 🔗

Global Finance News 10-07-26

Load More

10-19-26WS News

10-15-26The Investor

10-09-26Global Finance News

10-09-26Global Finance News

10-08-26European Investor

NASDAQ:GRMNFollow

Track all markets on TradingView - Prices are not updated in real time

Garmin Falls 1.1% Despite Record Q3 Revenue, Margin Expansion and Higher Guidance

Garmin (NYSE: GRMN) shares fell about 1.1% even after the company reported record third-quarter 2026 results and raised its full-year outlook.

Revenue increased 12% year over year to a record $1.99 billion. Gross margin expanded to 63.3%, while operating margin improved to 30.8%.

Operating income jumped 34% to a record $612 million. GAAP EPS reached $2.80, while pro forma EPS increased 39% year over year to $2.76.

Product momentum remained strong, with Garmin launching the fēnix 9 and fēnix 9 Pro smartwatch series. The company also highlighted continued strength in aviation, including delivery of its 1,000th G1000 retrofit for King Air aircraft and more than 2,500 aircraft equipped with Garmin Autoland.

Management raised its full-year guidance following the stronger quarter.

The 1.1% decline appears to reflect a muted market reaction or profit-taking rather than deterioration in the underlying business, as Garmin delivered double-digit sales growth, substantial margin expansion and sharply higher earnings.

💬 🔗

WS Investor 10-28-26

Garmin reported record first-quarter 2026 results, driven by strong revenue growth and expanding profitability.

Revenue rose 14% year-over-year to approximately $1.75 billion, marking a record for the first quarter. Profitability improved significantly, with operating income increasing 30% to $432 million, while operating margin expanded to 24.6% and gross margin to 59.4%.

Earnings also showed strong growth, with GAAP EPS reaching $2.09 and pro forma EPS at $2.08, up 29% from the prior year.

On the product side, Garmin highlighted continued innovation, including industry recognition for its Fenix 8 Pro, which was named “Best Connected Device” at the Mobile World Congress 2026.

The results reflect strong demand across Garmin’s product segments and effective cost management, supporting continued margin expansion.

Source: PR Newswire

💬 🔗

Global Finance News 04-30-26

Garmin announced that several of its aviation retrofit solutions have received certification from the European Union Aviation Safety Agency (EASA), expanding their availability across a wide range of aircraft in Europe.

The approvals include the GI 275 electronic flight display for helicopters, the G5000 integrated flight deck upgrade for Cessna Citation XLS+ aircraft, the Cirrus Perspective+ upgrade for SR Series planes, and a new digital distance measuring equipment (DME) solution.

These upgrades are designed to modernize cockpits, improve pilot situational awareness, reduce operational costs, and address obsolescence of legacy avionics systems.

Garmin said the certifications support its strategy to deliver advanced, scalable avionics solutions while enhancing safety and performance across general and business aviation.

💬 🔗

WS Investor 04-21-26

Garmin Ltd. introduced the D2 Mach 2 Pro, its first aviator smartwatch with satellite and cellular connectivity, enabling pilots to communicate and access data without a phone.

The device combines aviation tools, health monitoring, and emergency SOS features, targeting enhanced connectivity and safety for pilots.
PRNewswire

💬 🔗

WS Investor 04-14-26

Olathe, Kan., March 31, 2026 — Garmin announced a new integration with Natural Cycles, enabling users of select Garmin smartwatches to access an FDA-cleared birth control app powered by skin temperature data.

The integration allows users to track overnight skin temperature through compatible Garmin devices, with the data automatically syncing to the Natural Cycles app to provide personalized fertility insights. The app, classified as an FDA-approved medical device, helps users monitor fertility status for pregnancy planning or prevention.

The feature is available in multiple regions, including the United States, Europe, and the United Kingdom, and supports several Garmin smartwatch models. Both companies highlighted the move as a step toward expanding wearable-driven women’s health solutions and offering non-hormonal birth control alternatives.
PRNewsaire

💬 🔗

WS Investor 04-01-26

Garmin Ltd. (NYSE: GRMN) first quarter 2026 earnings conference call on Wednesday, April 29, 2026, at 10:30 a.m. EDT

💬 🔗

WS Investor 03-25-26

Garmin Ltd. expanded its Guided Visual Approaches aviation database, adding 15 new approaches and 10 airports including Long Beach and San Jose in California.

The system provides lateral and vertical guidance for pilots during visual approaches at challenging airports, helping stabilize landings and improve safety, especially in areas with difficult terrain or nighttime city lighting.

The update was developed with Hughes Aerospace and is available for purchase through Garmin’s aviation database services for compatible avionics systems.

💬 🔗

European Investor 03-12-26

Garmin introduced a new 360-degree scanning sonar system designed to give anglers a complete view of fish and underwater structures around their boats. The system combines the GT360UHD transducer with the new motorized Spy Pole, allowing users to see detailed 2D and 3D sonar imagery in every direction without constantly rescanning the water.

The system uses OneVü sonar technology and True Motion GPS integration to maintain accurate positioning of underwater targets while the boat moves. It can scan and store an area roughly the size of a football field and integrates with Garmin chartplotters for customized display settings and control. When paired with Garmin’s LiveScope sonar, anglers can also access enhanced 3D views and directional beam overlays.

The Spy Pole enables independent control of the sonar transducer separate from the trolling motor through wireless foot controls, a gesture remote or chartplotter interface. Garmin said the new sonar solution will debut at the 2026 Bassmaster Classic and will be available for purchase starting March 13.
PRNewswire

💬 🔗

European Investor 03-10-26

Garmin Ltd. (NYSE: GRMN) has launched a new Community Champions program to recognize local changemakers within the cities hosting its Garmin Marathon Series.

The initiative will highlight runners and fitness advocates who have made a positive impact in their communities through health, wellness and performance. In each host city, an application phase will be followed by the selection of three to five finalists. Finalists’ stories will be shared ahead of race day, and one Community Champion will be announced at the starting line, helping lead the official race countdown.

To be eligible, nominees must be at least 18 years old, live in or near a Garmin Marathon Series host city, and be present on race day. Submissions will be evaluated based on how individuals have inspired others to be active or contributed to their communities through running and fitness.

Applications are currently open for Durham, North Carolina, until March 31. Finalists are expected to be announced in early April, with the inaugural Community Champion revealed on May 2, 2026. Applications for Toledo, Ohio, and Tucson, Arizona, will open approximately two months before their respective race days.

The Garmin Marathon Series, wholly owned and produced by Garmin, launched in fall 2025 and includes marathon (Boston qualifier), half marathon, 10K and 5K distances. Registration remains open for all race distances across Durham, Toledo and Tucson.
PR Newswire

💬 🔗

The Investor 03-03-26

Garmin Ltd. announced new software and feature updates for select smartwatches, including Venu X1, vívoactive 6, fēnix 8 Pro, Forerunner 570 and Forerunner 970.

Key updates include enhanced gear tracking within the Garmin Connect app, allowing users to log more gear types, create gear collections, auto-assign equipment to activities and view gear lifespan progress directly on compatible watches.

New smartwatch features include a course planner for race preparation, live sports scores across 15 leagues (when paired with a smartphone), and mixed-session tracking for multiple activities in one workout. Garmin Fitness Coach now offers more personalized plans across 25+ activity types, while cyclists can receive Varia radar voice alerts on their watch.

Health additions include sleep alignment insights based on circadian rhythm and on-watch lifestyle logging for caffeine and alcohol, showing impacts on sleep, stress and HRV.

Additional updates target professional truck drivers with new road-focused tools and introduce expanded accessibility features, including spoken time and health data plus color display options for various forms of color blindness.

The free software updates are rolling out to compatible devices via Garmin Connect or Garmin Express.

Source: Garmin, February 24, 2026.

💬 🔗

The Investor 02-25-26

Load More

NYSE:UMCFollow

Track all markets on TradingView - Prices are not updated in real time

UMC Falls 3.4% Despite Strong Q3 Growth as Heavy Capacity Spending Weighs on Shares

United Microelectronics (NYSE: UMC) shares fell about 3.4% even after the company reported strong third-quarter 2026 revenue growth, higher utilization and record contribution from its 22nm business.

Revenue rose 25.6% year over year and 8.0% sequentially to NT$74.24 billion, or about $2.32 billion. Net income attributable to shareholders reached NT$16.43 billion, while gross margin was 34.0% and operating margin was 25.1%.

Operating conditions improved meaningfully. Wafer shipments increased 7.3% sequentially to a record level, while fab utilization reached 92%. Revenue from 22/28nm technologies accounted for 35% of wafer sales, with 22nm alone reaching a record 18.3%.

Management said demand remained healthy across all major markets and expects fourth-quarter shipments and utilization to remain stable. Advanced packaging and silicon photonics are also expected to contribute increasing revenue as new projects ramp.

However, UMC also announced an additional capital expenditure budget of about $3.2 billion to accelerate capacity expansion in Singapore and Tainan. The spending is intended to address rising customer demand and capacity constraints.

The 3.4% decline appears to reflect investor concern over the scale of the new capital spending and its near-term impact on cash flow and returns, which outweighed otherwise strong revenue growth, utilization and demand trends.

💬 🔗

WS Investor 10-28-26

Load More

S&P 500Follow

U.S. Stocks Trade Mixed as Wider Trade Deficit Offsets Inventory Growth

U.S. stocks were mixed after fresh economic data showed a wider-than-expected goods trade deficit alongside stronger retail inventory growth. The S&P 500 rose 0.15% and the Dow gained 0.27%, while the Nasdaq was nearly unchanged, down 0.01%.

The U.S. goods trade deficit widened to $134.90 billion in September, larger than the $130.40 billion consensus estimate and the previous $132.07 billion deficit. The deterioration suggests imports continued to outpace exports and could weigh on the trade component of third-quarter GDP calculations.

Retail inventories excluding autos increased 0.4% in September, accelerating from 0.1% previously. Higher inventories can provide some near-term support to GDP, although persistent inventory accumulation can become a negative signal if it reflects weaker-than-expected final demand.

Overall, the releases offered a mixed economic signal: stronger inventory accumulation was offset by a larger trade deficit, helping explain the relatively subdued reaction across major U.S. equity indexes.

💬 🔗

WS Investor 10-28-26

Wall Street Rises as Strong Consumer Confidence Offsets Mixed U.S. Economic Data

U.S. stocks moved higher Tuesday, with the Nasdaq gaining 1.19%, the S&P 500 rising 0.66% and the Dow Jones adding 0.14%, as investors digested a mixed batch of economic data.

Conference Board Consumer Confidence climbed to 91.7 in October, well above the 81.2 forecast and up from 84.2 previously. The stronger-than-expected reading pointed to improved household sentiment and provided the clearest positive signal from the day’s releases.

New home sales also came in better than expected at an annualized 676,000 in September, compared with the 651,000 forecast, although sales edged down from 680,000 previously.

Other indicators were softer. Building permits slipped to 1.398 million, slightly below the 1.400 million forecast and 1.403 million prior reading. Weekly ADP employment growth slowed to 16,800 from 18,500, suggesting some moderation in private-sector hiring.

Durable goods orders rose 1.8% in September, a sharp improvement from the prior 0.1% increase but slightly below the 2.0% consensus estimate.

Overall, the data presented a mixed economic picture, with stronger consumer confidence and housing demand offsetting softer employment and building activity. The stronger move in the Nasdaq suggests risk appetite remained relatively firm despite the uneven macro signals.

💬 🔗

European Investor 10-27-26

Wall Street Falls as Mixed Jobless Claims and Surging Oil Keep Rate and Inflation Concerns in Focus

U.S. stocks traded lower after the latest labor-market data sent a mixed signal while a sharp rise in crude oil added to inflation concerns.

Initial jobless claims fell to 194,000, better than the 200,000 consensus estimate and down from 200,000 previously. The reading suggests layoffs remain relatively contained and the labor market is still holding up.

Continuing jobless claims, however, rose to 1.728 million, above the 1.720 million forecast and up from 1.703 million previously. That points to some difficulty for unemployed workers in finding new jobs even as new layoffs remain low.

Equities were under pressure, with the S&P 500 down about 0.78%, the Dow Jones Industrial Average off 0.15%, and the Nasdaq falling roughly 1.42%. The heavier Nasdaq decline suggests continued pressure on rate-sensitive growth and technology stocks.

At the same time, Brent crude climbed about 2.4% to $111.48 per barrel. Higher oil prices can complicate the inflation outlook by increasing energy and transportation costs, potentially reinforcing concerns that the Federal Reserve may need to keep monetary policy restrictive for longer.

Overall, the combination of resilient initial claims and rising oil prices appears to be weighing on risk appetite, even as the increase in continuing claims points to some underlying softening in the labor market.

💬 🔗

WS News 10-22-26

Wall Street Trades Mixed as Hotter PPI and Strong Retail Sales Reinforce Rate Concerns

U.S. stocks traded mixed after a batch of economic data showed stronger consumer spending, hotter producer inflation and continued labor-market resilience. The S&P 500 fell 0.26% to 7,698.99 and the Nasdaq dropped 0.86% to 26,463.05, while the Dow Jones Industrial Average rose 0.55% to 51,907.65.

September retail sales increased 0.8% month over month, well above the 0.3% consensus estimate, although growth slowed from 1.3% previously. Core retail sales rose 0.9%, also beating the 0.6% forecast but easing from 1.4%.

Inflation data were more concerning. Producer prices jumped 1.3% month over month, more than double the 0.6% expected and sharply above the prior 0.5% increase. Core PPI rose 0.7%, compared with a 0.3% forecast and 0.2% previously.

The labor market remained firm. Initial jobless claims were 199,000, matching expectations and little changed from 198,000, while continuing claims came in at 1.710 million, exactly in line with forecasts and slightly below 1.714 million previously.

Manufacturing data were also much stronger than expected, with the New York Empire State Manufacturing Index jumping to 25.5 in October from 7.6, far above the 12.1 consensus estimate.

The data combination points to an economy that remains resilient but is also experiencing renewed inflation pressure. That backdrop may reinforce expectations for interest rates to remain elevated for longer, which appears to be weighing particularly on the rate-sensitive Nasdaq even as the Dow moves higher.

💬 🔗

The Investor 10-15-26

Wall Street Falls as September Inflation Comes in Hotter Than Expected

U.S. stocks moved lower after September inflation data showed broader price pressures remained firmer than economists expected. The S&P 500 fell 0.76% to 7,745.85, while the Nasdaq dropped 0.99% to 26,934.31. The Dow Jones Industrial Average declined 0.14% to 51,597.18.

Headline CPI increased 0.6% month over month in September, matching expectations but accelerating from 0.4% in August. On a year-over-year basis, inflation rose to 3.7%, above the 3.6% consensus estimate and up from 3.4% previously.

More importantly for the Federal Reserve outlook, core inflation also came in hotter than expected. Core CPI rose 0.3% month over month versus the 0.2% forecast, while the annual core rate accelerated to 2.6% from 2.4%, also exceeding the 2.5% consensus estimate.

The combination of higher headline inflation and an upside surprise in core prices suggests underlying inflation pressures remain persistent. That could reduce expectations for near-term monetary easing or reinforce the case for keeping interest rates elevated for longer.

The Nasdaq’s larger decline is consistent with renewed rate concerns weighing more heavily on growth and technology stocks, while the relatively smaller move in the Dow suggests a more defensive market response.

💬 🔗

Global Finance News 10-14-26

Wall Street Trades Mixed as U.S. Housing Data Beats Expectations

U.S. stocks traded mixed Tuesday as investors digested stronger-than-expected housing data alongside another increase in weekly private-sector employment.

The S&P 500 slipped 0.07% to 7,801.82, while the Nasdaq Composite fell 0.11% to 27,217.00. The Dow Jones Industrial Average was slightly higher, gaining 0.04% to 51,868.87.

U.S. existing home sales increased to an annualized 3.99 million units in September, above expectations of 3.95 million and up from 3.93 million previously. On a monthly basis, sales rose 1.5%, significantly stronger than the expected 0.8% decline and reversing the previous month’s 3.2% drop.

Separately, ADP’s weekly employment measure showed private payrolls increasing by 24,800, up from 23,800 in the previous reading.

The data points to continued resilience in parts of the U.S. economy, particularly housing and employment. However, the relatively muted equity-market reaction suggests investors remain cautious about how stronger economic activity could influence the Federal Reserve’s interest-rate outlook.

💬 🔗

European Investor 10-13-26

U.S. Stocks Edge Higher as Brent Crude Holds Near $104

U.S. stocks opened modestly higher on Thursday, with the S&P 500 up 0.27% at 7,786.27, the Dow Jones Industrial Average gaining 0.28% to 51,375.78, and the Nasdaq rising 0.34% to 27,285.85.

Brent crude was trading at $103.89 per barrel, down 0.37% on the day, after moving between roughly $102.50 and $103.90 during the session. Oil remains at elevated levels despite the slight decline.

The combination of firm equity markets and Brent holding above $100 suggests investors are balancing resilient risk appetite against continued inflation concerns from high energy prices. Elevated crude can increase transportation and input costs across the economy, potentially keeping some pressure on headline inflation.

For equities, the near-term question is whether oil prices stabilize around current levels or resume their recent rise. A renewed move higher in crude could revive concerns over inflation and interest rates, while a pullback would provide some relief to broader market sentiment.

💬 🔗

Global Finance News 10-09-26

U.S. Stocks Mixed as Rising Oil Prices Revive Inflation Concerns

U.S. stocks traded mixed on Thursday as investors weighed resilient labor-market data against a sharp rise in oil prices that renewed concerns about inflation.

The S&P 500 fell 0.17% to 7,788.26 and the Nasdaq declined 0.43% to 27,421.53, while the Dow Jones edged up 0.08% to 51,219.42.

Initial jobless claims came in at 197,000, below the 200,000 consensus and down from 199,000 previously, suggesting layoffs remain relatively limited. Continuing claims, however, increased to 1.716 million from 1.699 million, slightly above expectations of 1.710 million, pointing to somewhat softer re-employment conditions.

Oil added another source of pressure. Brent crude surged about 4.6% to roughly $104.83 per barrel during the session. The sharp increase raised concerns that higher energy costs could feed back into headline inflation and transportation costs, potentially slowing the disinflation process.

The combination of firm initial claims and rising oil prices is not particularly supportive for aggressive Federal Reserve easing. Investors appear to be balancing continued economic resilience against the risk that renewed energy inflation could keep interest rates higher for longer, which is especially relevant for rate-sensitive technology and growth stocks.

💬 🔗

European Investor 10-08-26

Wall Street Turns Lower as Inflation Expectations Rise and 10-Year Treasury Yield Jumps

U.S. stocks moved lower Wednesday as investors reacted to higher consumer inflation expectations and a sharp increase in the yield at the latest 10-year Treasury note auction.

The S&P 500 fell 0.24% to 7,800.42, while the Dow Jones Industrial Average declined 0.59% to 51,219.02. The Nasdaq Composite was down 0.39% at 27,492.49.

The New York Fed’s one-year consumer inflation expectations rose to 3.9% in September, above both the 3.6% forecast and the previous reading of 3.6%. The increase suggests households are becoming more concerned about near-term price pressures, potentially complicating the Federal Reserve’s path toward easier monetary policy.

Pressure on markets was reinforced by the U.S. Treasury’s 10-year note auction, which cleared at a yield of 5.300%, sharply above the previous auction’s 4.834%. The higher yield points to materially higher borrowing costs and increases the discount rate applied to future corporate earnings, a particular headwind for growth-oriented equities.

The combination of rising inflation expectations and higher long-term Treasury yields appears to be weighing on risk sentiment, with investors reassessing the possibility that U.S. interest rates may remain elevated for longer than previously anticipated.

💬 🔗

Global Finance News 10-07-26

Wall Street Opens Higher as ADP Weekly Employment Growth Strengthens

U.S. stocks opened higher on Tuesday, with the S&P 500 rising 0.79% to 7,835.09, the Dow Jones Industrial Average gaining 0.75% to 51,652.43 and the Nasdaq advancing 0.77% to 27,687.76.

The positive start came alongside a firmer reading from ADP’s weekly employment estimate. U.S. private-sector employment increased by 23,800, up from 22,500 in the previous reading, suggesting that labor demand remains relatively resilient.

The data added to the latest evidence that the U.S. labor market is continuing to expand, even as investors assess whether employment conditions are cooling enough to influence the Federal Reserve’s policy outlook.

Equities moved broadly higher at the open, with gains across all three major indexes. Markets are now likely to remain sensitive to upcoming labor, inflation and economic-growth data as investors reassess the timing and pace of any future changes in U.S. interest rates.

💬 🔗

The Investor 10-06-26

Load More

10-26-26WS News

10-19-26WS News

10-12-26WS News

10-08-26European Investor

10-07-26Global Finance News

NYSE:BSXFollow

Track all markets on TradingView - Prices are not updated in real time

Boston Scientific Falls 7% as Weak Q3 Growth and Soft Q4 Outlook Pressure Shares

Boston Scientific (NYSE: BSX) shares fell about 7% after the company reported only modest third-quarter 2026 sales growth, lower earnings and a weak fourth-quarter outlook.

Third-quarter sales increased just 1.5% year over year to $5.14 billion on both a reported and organic basis. GAAP EPS fell to $0.40 from $0.51, while adjusted EPS declined to $0.73 from $0.75.

Growth was subdued across major businesses. MedSurg sales increased only 0.7% organically, while Cardiovascular grew 1.9%. Geographically, U.S. sales rose just 0.5%, while APAC declined 1.1% operationally. Management also acknowledged that 2026 has been a challenging year, including disruption from a cybersecurity incident.

The near-term outlook was the bigger concern. Boston Scientific now expects fourth-quarter sales to decline approximately 1% to 3% year over year on both a reported and organic basis, with adjusted EPS of $0.77-$0.79.

For the full year, the company expects reported sales growth of about 4.25%, organic growth of roughly 3.75% and adjusted EPS of $3.16-$3.18.

The 7% decline appears to reflect investor disappointment with slowing organic growth, lower earnings and especially the projected fourth-quarter revenue contraction, which outweighed continued product approvals and pipeline progress.

💬 🔗

WS Investor 10-28-26

Boston Scientific Stock Edges Higher After Solid Q2 Results Despite Cautious Full-Year Outlook

Boston Scientific (NYSE: BSX) shares were up 1.3% on Wednesday following the company's second-quarter earnings report, as investors balanced another quarter of strong execution against a more moderate growth outlook for the second half of 2026.

The medical device maker reported second-quarter revenue of $5.44 billion, up 7.5% year over year, while organic sales increased 7.0%, reaching the high end of its guidance range. GAAP EPS rose to $0.61 from $0.53 a year earlier, while adjusted EPS climbed to $0.86, exceeding management's guidance of $0.82 to $0.84.

Performance remained broad-based across the portfolio. Cardiovascular revenue increased 8.3%, supported by continued demand for electrophysiology and structural heart products, while the MedSurg segment grew 5.9%. International markets also remained a key growth driver, with Asia-Pacific revenue rising 11.2% and Latin America and Canada posting 22.4% growth.

Boston Scientific continued to invest aggressively in future growth, including a $1.5 billion investment in MiRus to expand its structural heart platform. The company also announced positive clinical data for several cardiovascular technologies and continued advancing its next-generation electrophysiology portfolio.

Management updated its full-year 2026 guidance, forecasting reported revenue growth of 5.5% to 6.5%, organic revenue growth of 5% to 6%, and adjusted EPS of $3.28 to $3.32. Third-quarter guidance calls for reported and organic revenue growth of 3% to 5% and adjusted EPS of $0.80 to $0.82.

The positive share price reaction suggests investors focused on Boston Scientific's continued ability to outperform expectations and execute across its core businesses. While management expects growth to moderate from the exceptional pace seen in recent years, strong profitability, continued innovation, and leadership in high-growth cardiovascular markets continue to support confidence in the company's long-term outlook.

💬 🔗

The Investor 07-29-26

Boston Scientific Reports Strong Q2 2025 Results; Raises Guidance

Boston Scientific posted Q2 2025 net sales of $5.06 billion, a 22.8% year-over-year increase, surpassing guidance. GAAP net income rose to $797 million ($0.53/share) from $324 million a year ago, with adjusted EPS at $0.75, also exceeding expectations.

Highlights:
• Cardiovascular segment drove growth with 23.2% organic increase.
• U.S. sales surged 30.7%, while APAC rose 18%.
• Key approvals included FDA expansion for FARAPULSE™ and CE mark for WATCHMAN FLX™ Pro.
• Company completed acquisitions of Intera Oncology and SoniVie Ltd. to enhance its oncology and hypertension portfolios.

CEO Mike Mahoney credited the global team for strong performance and affirmed long-term growth momentum.

💬 🔗

The Investor 07-24-25

Boston Scientific Discontinues ACURATE Valve Systems Amid Regulatory Hurdles

Boston Scientific Corporation announced it will cease global sales of its ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems and withdraw efforts to obtain FDA approval in the U.S. and other markets. The decision follows discussions with regulators that introduced higher clinical and regulatory requirements, making continued investment in the product line prohibitively costly.

Despite this move, the company expects to meet its Q2 and full-year 2025 sales and adjusted EPS guidance, as issued in April. However, it is not reaffirming its GAAP EPS guidance at this time and will provide further updates in its Q2 earnings call.

The announcement includes forward-looking statements and cautions investors that actual outcomes may vary due to market, operational, regulatory, or geopolitical factors.

💬 🔗

The Investor 05-29-25

3 Tariff-Resistant US Healthcare Stocks to Consider Adding to Your Portfolio - The Smart Investor

Here are three healthcare stocks that could prove resilient against Trump’s raft of tariffs.

(thesmartinvestor.com.sg)

💬 🔗

European Investor 05-20-25

Boston Scientific has entered into an agreement to acquire SoniVie Ltd., a medical device company that developed the TIVUS Intravascular Ultrasound System. This investigational technology is designed to treat hypertension by denervating nerves surrounding blood vessels, specifically through renal artery denervation. The acquisition expands Boston Scientific’s interventional cardiology portfolio with an ultrasound-based alternative to existing renal denervation therapies.

Hypertension is a leading risk factor for cardiovascular disease, and existing treatments, including medications and lifestyle changes, are often insufficient. The TIVUS system uses ultrasound energy to penetrate tissue more deeply than radiofrequency-based methods, potentially enabling faster procedures with effective nerve ablation.

Boston Scientific currently holds a 10% equity stake in SoniVie. The acquisition involves an upfront payment of approximately $360 million for the remaining 90%, with up to $180 million in additional payments contingent on regulatory milestones. The transaction is expected to close in the first half of 2025. The company anticipates a slight dilutive effect on adjusted earnings in 2025, offset by internal cost efficiencies.

The TIVUS system remains an investigational device and is not yet approved for commercial use. Boston Scientific continues to expand its portfolio of innovative cardiovascular treatments through strategic acquisitions.

💬 🔗

Global Finance News 03-03-25

Boston Scientific Corporation has announced the completion of a €1.5 billion public offering of senior notes through its wholly owned finance subsidiary, American Medical Systems Europe B.V. The company had previously announced the pricing of these senior notes on February 21, 2025.

Additionally, Boston Scientific recently reported strong financial results for the fourth quarter and full year 2024, with CEO Mike Mahoney describing it as "one of the best years in the history of the company." The company continues to expand its cardiovascular portfolio, with acquisitions such as Bolt Medical, Inc., and Intera Oncology, Inc., aimed at strengthening its interventional cardiology and oncology offerings.

Boston Scientific will also participate in TD Cowen’s 45th Annual Health Care Conference in March 2025.

💬 🔗

Global Finance News 02-27-25

Boston Scientific Corporation has announced the pricing of €1.5 billion in senior notes through its wholly owned finance subsidiary, American Medical Systems Europe B.V. The issuance includes €850 million of 3.000% notes due 2031 and €650 million of 3.250% notes due 2034. The offering is expected to close on February 26, 2025, subject to customary conditions. The proceeds, combined with cash on hand, will be used to repay AMS Europe's 0.750% senior notes due March 8, 2025, and for general corporate purposes, including short-term investments, debt reduction, working capital, and potential acquisitions.

💬 🔗

WS Investor 02-22-25

Boston Scientific Corporation reported strong financial results for both the fourth quarter and full year of 2024. The company posted net sales of $4.561 billion for the fourth quarter, reflecting a 22.4% increase on a reported basis and a 19.5% rise on an organic basis, surpassing its guidance range. For the full year, net sales totaled $16.747 billion, marking a 17.6% increase compared to the previous year. The company also saw a rise in net income, with GAAP net income for the fourth quarter reaching $566 million, or $0.38 per share, up from $504 million or $0.34 per share in 2023. Adjusted EPS for the quarter was $0.70, higher than the previous year's $0.55.

The growth was driven by significant performance in the Cardiovascular segment, which saw a 28.8% increase in reported sales, and strong results from the United States, which contributed a 30.7% increase in reported sales. Boston Scientific also highlighted several key developments, including the approval of the FARAPULSE Pulsed Field Ablation System, positive clinical trial results for the WATCHMAN FLX Left Atrial Appendage Closure Device, and multiple strategic acquisitions. The company acquired Axonics, Inc. and Cortex, Inc., expanding its product offerings, while also announcing agreements to acquire Bolt Medical and Intera Oncology, further solidifying its position in the medical device industry.

💬 🔗

WS News 02-05-25

Load More

GermanyFollow

Track all markets on TradingView - Prices are not updated in real time

German Consumer Confidence Weakens Further in November

Germany’s GfK Consumer Climate index fell to -30.8 for November, weaker than the -30.1 consensus estimate and down from -30.6 previously.

The decline points to continued caution among German households and suggests consumer sentiment remains under pressure despite some recent improvement in broader business indicators.

Additionally, Germany’s latest 10-year Bund auction cleared at a yield of 3.370%, down sharply from 3.580% at the previous auction.

💬 🔗

WS Investor 10-28-26

German Business Confidence Improves in October as Expectations Strengthen

Germany’s Ifo Business Climate Index rose to 90.2 in October, slightly above the 90.0 consensus estimate and up from 89.9 previously.

Business expectations improved more clearly, climbing to 91.6 from 90.4 and beating the 90.0 forecast. The increase suggests German companies have become somewhat more optimistic about the months ahead.

However, the Current Assessment index fell to 88.8 from 89.5, missing expectations of 89.9. That indicates businesses still see present economic conditions as relatively weak.

Overall, the report sends a mixed but mildly positive signal: current conditions deteriorated, but stronger expectations lifted the headline business climate index. The data suggest sentiment toward Germany’s future outlook is improving even though near-term activity remains soft.

💬 🔗

WS News 10-26-26

Eurozone ZEW Economic Sentiment Falls More Than Expected in October

Eurozone investor sentiment weakened in October, with the ZEW Economic Sentiment index falling to 18.5 from 25.8 previously.

The reading came in well below the 23.6 consensus estimate, signaling a more cautious outlook among financial-market experts.

The decline suggests that expectations for the euro-area economy have deteriorated despite some improvement in current conditions in Germany.

💬 🔗

WS News 10-20-26

German Producer Prices Accelerate as ZEW Signals Mixed Economic Outlook

German producer prices rose 1.9% month over month in September, exceeding the 1.5% consensus estimate and accelerating from a 1.1% increase previously.

The stronger-than-expected PPI reading points to renewed upstream price pressure, which could complicate the inflation outlook if higher producer costs begin feeding through to consumer prices.

Meanwhile, Germany’s ZEW Current Conditions index improved sharply to -35.9 in October from -47.1, substantially better than the -45.0 consensus estimate. Although the index remained negative, the improvement suggests respondents viewed the present economic environment as less weak than previously.

In contrast, ZEW Economic Sentiment fell to 28.1 from 34.7 and missed the 30.2 forecast, indicating that expectations for the months ahead have softened.

Overall, the data present a mixed picture: current conditions improved more than expected, but forward-looking sentiment weakened, while stronger producer-price growth adds a more inflationary element to the outlook.

💬 🔗

WS News 10-20-26

Eurozone Industrial Production Falls 0.5% in August, Missing Expectations

Eurozone industrial production declined 0.5% month over month in August, weaker than expectations for no change.

The result also marked a further deterioration from the previous month’s 0.3% decline, pointing to continued softness in the region’s manufacturing and industrial sectors.

💬 🔗

WS News 10-15-26

German Inflation Accelerates to 3.3% in September

Germany’s consumer price index rose 0.6% month over month in September, matching market expectations and accelerating from a 0.2% increase in August.

On an annual basis, inflation climbed to 3.3%, also in line with forecasts but up from 2.9% in the previous month.

💬 🔗

The Investor 10-13-26

German Trade Surplus Narrows in August but Beats Expectations

Germany’s trade surplus came in at €19.5 billion in August, above the €19.0 billion market consensus but down from €21.6 billion previously.

The smaller surplus indicates that the gap between exports and imports narrowed during the month, although the result was slightly better than economists had expected.

💬 🔗

The Investor 10-08-26

German Industrial Production Rebounds 2.0% in August

German industrial production rose 2.0% month over month in August, significantly beating expectations for a 0.5% increase and reversing the previous month’s 1.2% decline.

The stronger-than-expected rebound suggests that activity in Germany’s industrial sector improved more sharply than anticipated during the month.

The data provides a modestly positive signal for Europe’s largest economy, although the broader manufacturing outlook remains mixed following recent weakness in factory orders and external demand.

💬 🔗

European Investor 10-07-26

German factory orders fell 10.6% month over month in August, sharply missing expectations for a 0.9% decline and reversing a 3.2% increase in the previous month.

The steep drop points to renewed weakness in Germany’s manufacturing sector and suggests demand conditions remain fragile.

The weaker-than-expected reading may add to concerns over the outlook for Europe’s largest economy, particularly as manufacturers continue to face soft external demand and elevated financing costs.

💬 🔗

Global Finance News 10-06-26

Eurozone Services Activity Strengthens in September, Led by Spain

Eurozone services activity improved in September, with the HCOB Services PMI rising to 53.0 from 51.6, matching expectations and signaling a firmer pace of expansion across the region.

Spain remained the standout performer. Its services PMI climbed to 58.3 from 57.8, beating the 57.1 consensus and pointing to strong growth in the sector.

Germany’s services PMI improved sharply to 52.9 from 49.7, moving back into expansion and matching expectations. France also returned to growth, with its services PMI rising to 51.2 from 48.0, although the reading came in slightly below the 51.4 forecast.

Italy was the main weak spot. Its services PMI fell to 51.7 from 55.2, well below expectations of 54.6, though it still remained above the 50 threshold.

The Eurozone Composite PMI increased to 53.1 from 52.0, confirming broader improvement in overall business activity. Taken together, the data point to stronger regional momentum heading into the fourth quarter, with Spain and Germany providing the clearest support.

💬 🔗

European Investor 10-05-26

Load More

09-04-26WS Investor

01-27-26European Investor

11-21-25WS News

07-25-25WS Investor

07-21-25WS News

NASDAQ:GEHCFollow

Track all markets on TradingView - Prices are not updated in real time

GE HealthCare Jumps 7.8% as Q3 Growth, Margin Expansion and Raised Guidance Impress Investors

GE HealthCare (NASDAQ: GEHC) shares rose about 7.8% after the company reported stronger-than-expected third-quarter 2026 results and raised its full-year outlook.

Revenue increased 7.2% year over year to $5.5 billion, with organic growth of 6.2% across all segments. Organic orders rose 4%, book-to-bill was 1.03x and backlog reached $23.7 billion.

Profitability improved sharply. Adjusted EBIT rose to $913 million from $761 million, while adjusted EBIT margin expanded 180 basis points to 16.6%. Adjusted EPS increased 25% to $1.34, and GAAP EPS rose 39% to $1.36.

Segment performance was broad-based. Advanced Imaging Solutions revenue grew 6.1%, Pharmaceutical Diagnostics rose 13%, and Patient Care Solutions increased 8.5%. Patient Care Solutions EBIT jumped nearly 149%, with margin expanding 480 basis points.

Cash generation was also strong, with operating cash flow of $907 million and free cash flow of $793 million. The company raised its quarterly dividend by 14% and separately announced plans to acquire SOFIE Biosciences for $945 million.

GE HealthCare raised 2026 adjusted EPS guidance to $4.95-$5.05 from $4.80-$5.00 and now expects organic revenue growth of about 4%. The 7.8% gain appears to reflect the combination of stronger-than-expected growth, meaningful margin expansion, robust cash flow and higher full-year guidance.

💬 🔗

WS Investor 10-28-26

GE HealthCare reported mixed first-quarter 2026 results, with solid revenue growth offset by margin pressure and lower earnings.

Revenue increased 7.4% year-over-year to $5.1 billion, supported by demand in Pharmaceutical Diagnostics, imaging, and services, with organic growth of 2.9%. Orders grew modestly by 1.1% organically, with a book-to-bill ratio of 1.07 and a backlog of $21.8 billion.

Profitability declined, as net income fell to $389 million and diluted EPS dropped to $0.85 from $1.23 a year earlier. Adjusted EBIT margin decreased to 13.5%, impacted by a supplier issue in Pharmaceutical Diagnostics, tariffs, and rising input costs such as chips, oil, and freight.

While the supplier issue has been resolved, inflationary pressures led the company to lower its full-year profit and free cash flow outlook, even as it maintained its revenue growth expectations.

GE HealthCare expects mid- to high-single-digit adjusted EPS growth for 2026, supported by pricing actions, cost controls, and continued innovation.

Source: Business Wire

💬 🔗

Global Finance News 04-30-26

GE HealthCare announced an expanded collaboration with DeepHealth, a subsidiary of RadNet, to advance the global adoption of AI-powered breast cancer screening solutions.

The partnership builds on an earlier initiative by integrating DeepHealth’s AI-driven Breast Suite with GE HealthCare’s mammography systems, aiming to improve diagnostic accuracy, workflow efficiency, and early cancer detection. The enhanced platform includes tools such as automated lesion detection, density assessment, and AI-assisted case prioritization.

Clinical data cited in the release indicates that the AI-powered workflow can increase breast cancer detection rates by around 21%, with even higher improvements for patients with dense breast tissue. The companies plan to expand access to these technologies globally, supporting more scalable and efficient screening programs.
Business Wire

💬 🔗

Global Finance News 04-17-26

GE HealthCare and Medtronic Integrate Surgical Imaging and Navigation Systems

GE HealthCare announced a digital integration between its bkActiv intraoperative ultrasound system and Medtronic’s Stealth AXiS surgical navigation platform.

The integration enables neurosurgeons to access real-time imaging during cranial procedures, combining ultrasound visualization with surgical navigation and robotics in a unified workflow. The system is designed to improve precision and decision-making by allowing surgeons to monitor anatomical changes, such as brain shift, during operations.

The Stealth AXiS system recently received FDA clearance for cranial procedures in the U.S., and the combined solution will be showcased at an upcoming neurosurgery conference in May 2026.

The collaboration builds on an existing partnership between the two companies, aimed at advancing next-generation surgical technologies and improving clinical outcomes.
Business Wire

💬 🔗

WS Investor 04-09-26

GE HealthCare to announce first quarter 2026 results on April 29, 2026

💬 🔗

Global Finance News 04-07-26

GE HealthCare has announced a leading industrial role in the COMPASS consortium, one of the largest EU-funded public-private partnerships under the Innovative Health Initiative, aimed at advancing cardio-oncology care across Europe.

The five-year project, with a total budget of €50.5 million and more than 60 partners, focuses on improving early detection and prediction of cardiovascular complications in cancer patients and survivors. The initiative will leverage artificial intelligence, advanced imaging technologies, biomarkers, and integrated care pathways to address cardiotoxicity risks associated with cancer treatments.

Cardiovascular disease has emerged as a major cause of mortality among cancer survivors, accounting for up to 10% of deaths. COMPASS aims to tackle this challenge by developing predictive tools, identifying novel biomarkers, and enabling more personalized and coordinated care between oncology and cardiology disciplines.

Co-funded under the EU’s Horizon Europe program, the consortium seeks to translate scientific and technological innovations into routine clinical practice, improving long-term outcomes and reducing healthcare system pressure across Europe.
Business Wire

💬 🔗

Global Finance News 03-27-26

GE HealthCare unveils AI-powered cardiology innovations at ACC.26

March 25, 2026 — GE HealthCare announced it will showcase a range of advanced cardiology technologies at ACC.26, including new AI-enabled imaging systems, software solutions, and strategic collaborations aimed at improving heart disease diagnosis and treatment.

Among the highlights is the newly FDA-cleared Photonova Spectra photon-counting CT system, designed to deliver ultra-high-definition cardiac imaging and improved tissue characterization. The company will also present its ReadyFix fleet management solution, which uses real-time data to optimize performance and uptime of ECG systems.

In addition, GE HealthCare revealed a collaboration with Gentuity to enhance imaging capabilities in cardiac catheterization procedures, supporting more precise treatment planning and execution.

The company said its latest innovations aim to help clinicians detect cardiovascular disease earlier, improve decision-making, and deliver more personalized patient care amid rising global demand.
Business Wire

💬 🔗

WS Investor 03-25-26

GE HealthCare announced that its Photonova Spectra photon-counting CT system has received FDA clearance, marking a key step toward commercial deployment in the U.S.

The system introduces advanced photon-counting technology with ultra-high resolution imaging and improved tissue characterization, enabling clinicians to detect subtle abnormalities and make more precise diagnoses from a single scan.

Designed to handle significantly larger data volumes using NVIDIA-powered computing, the platform aims to enhance workflow efficiency and support more accurate, data-rich clinical decision-making.
Business Wire

💬 🔗

WS Investor 03-23-26

GE HealthCare announced the completion of its $2.3 billion acquisition of Intelerad, a medical imaging software provider, strengthening its shift toward cloud-based and AI-enabled enterprise imaging solutions.

The acquisition expands GE HealthCare’s presence beyond hospitals into ambulatory and specialized care settings, enabling a more comprehensive, end-to-end imaging ecosystem. Intelerad’s cloud-native technology is expected to enhance workflow efficiency, reduce infrastructure costs, and support faster deployment of imaging solutions.

Financially, Intelerad is expected to generate around $270 million in annual revenue with a high share of recurring income and EBITDA margins above 30%. The deal is anticipated to support long-term growth and profitability, although it may be slightly dilutive to earnings per share in the short term due to financing costs.
Business wire

💬 🔗

Global Finance News 03-19-26

GE HealthCare announced that its next-generation diagnostic imaging viewer, View, has received U.S. FDA 510(k) clearance.

The cloud-native viewer is part of the Genesis Radiology Workspace and is designed to allow radiologists to securely access and interpret medical images from virtually anywhere. The platform includes high-performance 2D and 3D visualization along with AI-enabled tools that support faster clinical decision-making and improved workflow efficiency.

GE HealthCare said the system aims to streamline radiology workflows and reduce time spent on non-interpretive tasks—currently estimated to account for up to 44% of radiologists’ work—helping clinicians analyze images more efficiently and improve patient care.
Source: Business Wire

💬 🔗

WS Investor 03-09-26

Load More

01-29-26Global Finance News

10-24-25WS News

NYSE:UBSFollow

Track all markets on TradingView - Prices are not updated in real time

UBS Slips 0.8% Despite Strong Q3 Profit and Wealth Management Inflows

UBS shares fell about 0.8% despite reporting strong third-quarter 2026 earnings, robust wealth-management inflows and continued progress on the Credit Suisse integration.

Net profit reached $2.7 billion, while profit before tax rose 27% year over year to $3.59 billion. On an underlying basis, pretax profit increased 14% to $4.08 billion. Reported revenue rose 5% to $13.35 billion, while underlying revenue increased 10%.

Client momentum remained strong. Global Wealth Management attracted $55.1 billion of net new assets, while underlying Global Markets revenue increased 17%, led by a 22% rise in Equities. Group invested assets reached $7.3 trillion.

UBS also continued to exceed integration targets. Gross cost savings reached $13.2 billion, and the bank now expects cumulative savings of about $13.7 billion by year-end, above its previous $13.5 billion ambition.

Capital remained solid, with a CET1 ratio of 14.7%. UBS repurchased $1.8 billion of shares during the quarter and still plans to complete its $3 billion buyback program by the time it reports fourth-quarter results.

The 0.8% decline appears to reflect caution around the outlook rather than weakness in the quarter itself. UBS expects normal seasonal moderation in fourth-quarter transaction volumes, while uncertainty over future Swiss capital requirements remains an important overhang for shareholders.

💬 🔗

WS Investor 10-28-26

UBS Discloses Substantial Holding in The a2 Milk Company

UBS Group AG and its related entities disclosed to NZX Limited and The a2 Milk Company Limited that they have become a substantial holder of the company’s ordinary shares. The holding began on May 21, 2025. UBS and its related corporate entities now collectively own 36,286,808 shares, representing approximately 5.01% of the total 724,019,118 shares on issue.

This holding comprises various types of interests, including fund management control, prime brokerage rights, beneficial ownership, and derivative positions (such as cash-settled swaps and options). These interests are distributed across multiple UBS entities including UBS AG’s Australia and London branches, UBS Securities Australia Ltd, and UBS Asset Management divisions in several countries.

💬 🔗

European Investor 05-26-25

Load More

04-30-25The Investor

04-01-25WS News